| If you are new to the world of Microsoft Small Business Server 2003, Microsoft Small Business Server 2003 Unleashed can provide you with real-world support experience as you get started or explore your upgraded server. Written and reviewed by Small Business Server MVPs, this book provides valuable coverage of Mac and Linux platform integration, as well as the integration of ISA 2004, SharePoint, FrontPage, Exchange, and SQL Server. You will develop a number of new skills, including:
-
Planning SBS installations.
-
Troubleshooting SBS installation problems.
-
Adding additional servers to the SBS network.
-
Troubleshooting common Exchange problems.
-
Working with ISA 2004 in the SBS environment.
-
Troubleshooting common IIS problems in SBS.
-
Working with SharePoint Team Services and the Companyweb interface.
-
Configuring SBS and Macintosh clients for integrating the two platforms.
Make complex networking accessible with Microsoft Small Business Server 2003 Unleashed. |
|
|
 The Finite Element Method and Applications in Engineering Using ANSYS®
This textbook offers theoretical and practical knowledge of the finite element method. The book equips readers with the skills required to analyze engineering problems using ANSYS®, a commercially available FEA program. Revised and updated, this new edition presents the most current ANSYS® commands and ANSYS® screen shots, as well... |  |  Newton: A Very Short IntroductionThis Very Short Introduction uses Newton's own unpublished writings to provide fascinating insight into the man who kept the Royal Society under his thumb, was Head of the Mint, and whose contributions to our understanding of the heavens and the earth are considered by many to be unparalleled. The author begins with the legends surrounding... |  |  Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition
Extensively revised and updated, Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition reflects the logarithmic progress made in the past four years of oligonucleotide-based therapies, and, in particular, antisense therapeutics and research. Interpreting lessons learned from the clinical trials of first... |
|